Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC)
In: Journal of Clinical Oncology, Jg. 34 (2016-05-20), S. 518-518
Online
unknown
Zugriff:
518Background: In HER2+ EBC pCR rates after neoadjuvant chemo (CT)+/- anti-HER2 therapy differ according to hormone receptor (HR) status. The neoadjuvant ADAPT HER2+/HR- phase II trial aims to iden...
Titel: |
Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC)
|
---|---|
Autor/in / Beteiligte Person: | Hans Holger Fischer ; Augustin, Doris ; Forstbauer, Helmut ; Wuerstlein, Rachel ; Christgen, Matthias ; Grischke, Eva-Maria ; Nitz, Ulrike ; Stefek, Andrea ; Kreipe, Hans ; Liedtke, Cornelia ; Braun, Michael ; Kümmel, Sherko ; Schumacher, Claudia ; Kohls, A. ; Potenberg, Jochem ; Reimer, Toralf ; Gluz, Oleg ; Krauss, Katja ; Harbeck, Nadia |
Link: | |
Zeitschrift: | Journal of Clinical Oncology, Jg. 34 (2016-05-20), S. 518-518 |
Veröffentlichung: | American Society of Clinical Oncology (ASCO), 2016 |
Medientyp: | unknown |
ISSN: | 1527-7755 (print) ; 0732-183X (print) |
DOI: | 10.1200/jco.2016.34.15_suppl.518 |
Schlagwort: |
|
Sonstiges: |
|